calendar
2 catalysts · 25 phase 2 completion · 20 phase 1 completion · 19 phase 1 2 completion · 11 phase 1 initiation · 9 phase 1 2 initiation · 4 phase 0 trial completion
next 91 dayslessmore
MonWedFri
2 catalysts · 25 phase 2 completion · 20 phase 1 completion · 19 phase 1 2 completion · 11 phase 1 initiation · 9 phase 1 2 initiation · 4 phase 0 trial completion
Therapy area: Oncology. Indication: Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Therapy area: Oncology. Indication: Hormone-Sensitive Prostate Cancer